欧州連合 - フィンランド語 - EMA (European Medicines Agency)

lipomed gmbh - talidomidin - multiple myeloma - immunosuppressantit - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.

欧州連合 - フィンランド語 - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - multiple myeloma - antineoplastiset aineet - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

欧州連合 - フィンランド語 - EMA (European Medicines Agency)

csl behring gmbh - etranacogene dezaparvovec - hemofilia b - other hematological agents - treatment of severe and moderately severe haemophilia b (congenital factor ix deficiency) in adult patients without a history of factor ix inhibitors.

欧州連合 - フィンランド語 - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - antineoplastiset aineet - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

欧州連合 - フィンランド語 - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - multiple myeloma - antineoplastiset aineet - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

欧州連合 - フィンランド語 - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastiset aineet - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

フィンランド - フィンランド語 - Fimea (Suomen lääkevirasto)

actavis nordic a/s regulatory affairs - risperidonum - tabletti, kalvopäällysteinen - 0.5 mg - risperidoni

フィンランド - フィンランド語 - Fimea (Suomen lääkevirasto)

actavis nordic a/s regulatory affairs - risperidonum - tabletti, kalvopäällysteinen - 1 mg - risperidoni

フィンランド - フィンランド語 - Fimea (Suomen lääkevirasto)

actavis nordic a/s regulatory affairs - risperidonum - tabletti, kalvopäällysteinen - 2 mg - risperidoni

フィンランド - フィンランド語 - Fimea (Suomen lääkevirasto)

actavis nordic a/s regulatory affairs - risperidonum - tabletti, kalvopäällysteinen - 3 mg - risperidoni